A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease
Status:
Completed
Trial end date:
2018-08-31
Target enrollment:
Participant gender:
Summary
This is a study to evaluate biodistribution, pharmacokinetics and safety of [18F]THK-5351
positron emission computed tomography in Cognitively Healthy Subjects and Patients with
Alzheimer's Disease.